This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
PRDS Aktienübersicht
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Belohnungen
Risikoanalyse
Pardes Biosciences, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$3.67 |
| 52 Week Low | US$0.75 |
| Beta | 0.42 |
| 1 Month Change | 2.37% |
| 3 Month Change | 14.29% |
| 1 Year Change | -40.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.98% |
Aktuelle Nachrichten und Updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Aktionärsrenditen
| PRDS | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.5% | 0.2% | 1.0% |
| 1Y | -40.0% | 8.4% | 21.8% |
Preisvolatilität
| PRDS volatility | |
|---|---|
| PRDS Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2020 | 57 | Tom Wiggans | www.pardesbio.com |
Pardes Biosciences, Inc.'s Grundlagenzusammenfassung
| PRDS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$131.19m |
| Gewinn(TTM) | -US$76.14m |
| Umsatz(TTM) | n/a |
0.0x
Kurs-Umsatz-Verhältnis-1.7x
Kurs-Gewinn-VerhältnisIst PRDS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PRDS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$0 |
| Kosten der Einnahmen | US$0 |
| Bruttogewinn | US$0 |
| Sonstige Ausgaben | US$76.14m |
| Umsatz | -US$76.14m |
Zuletzt gemeldete Gewinne
Jun 30, 2023
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.25 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich PRDS auf lange Sicht entwickelt?
Historische Performance und Vergleiche